We have designed and synthesized a series of HIV protease inhibitors (PIs) with enamino-oxindole substituents optimized to interact with the S2' subsite of the HIV protease binding pocket. Several of these inhibitors have sub-nanomolar K-i and antiviral IC50 in the low nM range against WT HIV and against a panel of multi-drug resistant (MDR) strains. (C) 2012 Elsevier Ltd. All rights reserved.
We have designed and synthesized a series of HIV protease inhibitors (PIs) with enamino-oxindole substituents optimized to interact with the S2' subsite of the HIV protease binding pocket. Several of these inhibitors have sub-nanomolar K-i and antiviral IC50 in the low nM range against WT HIV and against a panel of multi-drug resistant (MDR) strains. (C) 2012 Elsevier Ltd. All rights reserved.